Table 2.
Estimated vaccine effectiveness against COVID-19 outcomes 14 to 84 days after matching of the first dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccines.
| Documented SARS-CoV-2 infection | COVID-19 hospitalisation* | COVID-19 mortality ¥ | All-cause mortality | |
|---|---|---|---|---|
| Number of events (rate per 1000 person-years [95%CI]) | ||||
| Unvaccinated [U] | 288 (18.23 [16.24 to 20.46]) |
51 (3.20 [2.43 to 4.21]) |
25 (1.57 [1.06 to 2.32]) |
154 (9.65 [8.24 to 11.31]) |
| Oxford-AstraZeneca [AZ] | 136 (15.11 [12.77 to 17.88]) |
7 (0.77 [0.37 to 1.62]) |
2 (0.22 [0.06 to 0.88]) |
21 (2.31 [1.51 to 3.55]) |
| Pfizer-BioNTech [P] | 110 (12.44 [10.32 to 14.99]) |
7 (0.78 [0.37 to 1.65]) |
2 (0.22 [0.06 to 0.90]) |
15 (1.68 [1.01 to 2.79]) |
| Incidence rate ratios (95%CI) – p-value) | ||||
| AZ vs U | 0.85 (0.69 to 1.05) - p = 0.121 | 0.25 (0.09 to 0.55) - p < 0.001 | 0.14 (0.02 to 0.58) - p < 0.001 | 0.25 (0.15 to 0.39) - p < 0.001 |
| P vs U | 0.69 (0.55 to 0.86) - p < 0.001 | 0.25 (0.09 to 0.55) - p < 0.001 | 0.14 (0.02 to 0.58) - p < 0.001 | 0.18 (0.10 to 0.30) - p < 0.001 |
| P vs AZ | 0.81 (0.62 to 1.05) - p = 0.098 | 1.00 (0.30 to 3.34) - p = 1.000 | 1.00 (0.07 to 13.80) - p = 1.000 | 0.71 (0.34 to 1.45) - p = 0.324 |
⁎
COVID-19 hospitalisation defined as having a positive documented SARS-CoV-2 test 14 days before or within 7 days of being admitted to hospital.
¥
COVID-19 mortality defined as having a positive documented SARS-CoV-2 test 28 days prior to death.